Skip to content
← All settings

DISEASE & TREATMENT SETTING

TRODELVY: unresectable metastatic Breast cancer with PD-L1 stated without a specific alteration (first-line)

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy.

Broader topic: Breast Cancer

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
first-line
Stage
Not part of this definition
Resectability
unresectable
Biomarkers, prior therapy and derivation
molecular
  1. gene
    PD-L1
    alteration
    stated without a specific alteration
    status
    present
prior therapy
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for TRODELVY (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy.

    Study evidence for this setting

    3 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice